Humira The drug that caused the most increased spending by far was Humira, a rheumatoid arthritis drug. (Photo: JB Reed/Bloomberg)

Drug price increases that were not supported by clinical improvements raised health care costs in the U.S. by about $1.67 billion in 2020, a new report said.

The report, released by The Institute for Clinical and Economic Review (ICER) said that among the top 10 drugs with price increases last year that had substantial effects on US spending, seven of 10 drugs did not have new evidence of a new clinical benefit. The group said these unsupported drug price increases cost the U.S. health system $1.67 billion, even after pharmaceutical rebates and other concessions.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Health Care Reform
Employer-Paid